Overview
ZLAB market data
Price History
ZLAB price chart · 1M
- O
- 27.17
- H
- 27.17
- L
- 26.65
- C
- 26.82
- Vol
- 33,735.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $27.17
- Previous Close
- $26.03
- Day High
- $27.17
- Day Low
- $26.65
- 52 Week High
- $27.33
- 52 Week Low
- $16.28
- 7 Day Return
- +3.07%
- 30 Day Return
- +43.88%
- 90 Day Return
- +51.53%
- 1 Year Return
- +29.07%
- Daily Notional Volume
- $904.8K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.16 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.46 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -41.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $12.31 – $27.36 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $23.2B · P/B 2.75 · P/S 6.57.
Company News
Citigroup Maintains Buy on Zai Lab, Raises Price Target to $45Benzinga · Aug 7, 2026, 8:12 PM
Zai Lab shares are trading higher after the company reported better-than-expected Q2 sales results.Benzinga · Aug 6, 2026, 6:35 PM
8-K filing — Zai Lab Ltd (ZLAB)SEC EDGAR · Aug 6, 2026, 10:34 AM
Zai Lab Q2 EPS $(0.46) Misses $(0.06) Estimate, Sales $105.751M Beat $105.323M EstimateBenzinga · Aug 6, 2026, 10:32 AM
Zai Lab Says FDA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3 Antibody-Drug Conjugate, For Treatment Of Neuroendocrine CarcinomasBenzinga · Aug 3, 2026, 11:27 AM
Zai Lab Announces EMA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3-Targeting Antibody-Drug Conjugate, For Treatment Of Pulmonary Neuroendocrine CarcinomasBenzinga · Jun 16, 2026, 11:20 AM